This antibody reacts with Human C3a and C3adesArg (67-76). It does not cross-react with C3 or C4a.
Purification
Affinity Chromatography
Immunogen
Peptide coupled to carrier protein. The antibody was generated against the carboxy-terminal neoepitope which is not exposed on C3, allowing discrimination between C3 and C3a.
C3
Reactivity: Human
WB, ELISA
Host: Mouse
Polyclonal
unconjugated
Application Notes
ELISA. The titer with native human C3a was 1: 5000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS, pH 7.2, 0.09 % Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
This product is photosensitive and should be protected from light
Storage
4 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month. DO NOT FREEZE!
The complement system is part of the innate immune system representing humoral defence. Activation of the complement cascade via the classical, the alternative or the Lectin pathway liberates several biologically active by-products, among them the anaphylatoxin C3a. Measurement of C3a (and C4a) in plasma or other body fluids can yield important clues about the pathological, and particularly also the inflammatory status of an organism. In serum, C3a activity is under strict control of the carboxypeptidase N. This enzyme rapidly cleaves the C-terminal arginine, thereby generating C3adesArg which shows greatly reduced biological activity as compared to C3a. Thus, the biological activity of C3a is focused mainly on its point of generation, while the degradation product C3adesArg remains relatively stable until it is cleared from the circulation.Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, CPAMD1, Complement component 3